Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for TRSBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TRSBF and 80,000+ other tickers.
See exactly how TRSBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TRSBF and 80,000+ other tickers.
3SBio Inc. is a China-based investment holding company deeply engaged in the biopharmaceutical sector, encompassing the entire value chain from research and development to manufacturing, marketing, and sales of its innovative products. The company's extensive biopharmaceutical portfolio caters to a wide array of therapeutic needs. This includes treatments for various blood disorders like TPIAO (for chemotherapy-induced or immune thrombocytopenia), EPIAO and SEPO (recombinant erythropoietins for anemia), and SPARIN (a low-molecular-weight heparin for deep vein thrombosis prophylaxis and…
3SBio Inc. (OTCMKTS:TRSBF - Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 14,802,882 shares, a growth of 142.1% from the June 30th total of 6,115,388 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is
3SBio (OTCMKTS:TRSBF - Get Free Report) is projected to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of $0.5160 per share and revenue of $1.9761 billion for the quarter. 3SBio Price Performance Shares of OTCMKTS TRSBF opened at $2.58 on Monday. 3SBio has a twelve